Aclaris Therapeutics Inc (ACRS):製薬・医療:M&Aディール及び事業提携情報

GlobalDataが発行した調査報告書(DATA904C9424)
◆英語タイトル:Aclaris Therapeutics Inc (ACRS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9424
◆発行会社(リサーチ会社):GlobalData
◆発行日:2018年11月
◆ページ数:72
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
Aclaris Therapeutics Inc (Aclaris Therapeutics) is a dermatologist-led bio-pharmaceutical company which focuses on identifying, developing, and commercializing prescription drug products for unmet needs in aesthetic and medical dermatology as well as immunology. Its lead product, ESKATA, is a proprietary formulation of high-concentration hydrogen peroxide topical solution prescribed for the treatment of raised seborrheic keratosis (SK). The company’s pipeline products include A-101, ATI-502, ATI-501, ATI-450-MK-2 inhibitor, soft JAK inhibitor, ITK oral anti-IL17 and ITK topical anti-IL17. Aclaris Therapeutics’ pipeline products are used for the treatment of common warts, alopecia areata, androgenetic alopecia, psoriasis, arthritis, gangrenosum, inflammatory skin diseases, atopic dermatitis and others. The company also develops investigational drugs to treat skin and hair conditions. Aclaris Therapeutics is headquartered in Wayne, Pennsylvania, the US.

Aclaris Therapeutics Inc (ACRS) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Aclaris Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Aclaris Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Aclaris Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Aclaris Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Aclaris Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10
Aclaris Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Aclaris Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
Aclaris Therapeutics to Acquire Worldwide Rights of RHOFADE from Allergan Sales 13
Venture Financing 14
Confluence Life Sciences Raises USD4.8 Million in Financing 14
Aclaris Therapeutics Raises USD40 Million in Series C Financing 15
Confluence Life Sciences Raises USD2.4 Million in Post Seed Financing Round 17
Aclaris Therapeutics Raises USD21 Million in Series B Venture Financing 18
Confluence Life Sciences Raises Funds Through Venture Financing 19
Confluence Life Sciences Secures USD0.5 Million in Series A Funding Round 20
Aclaris Therapeutics Raises US$21 Million In Series A Financing 21
Confluence Life Sciences Raises US$4 Million In Series A Financing 23
Partnerships 24
Aclaris Therapeutics Enters Into Licensing Agreement with JAKPharm and Key Organics 24
Licensing Agreements 25
Cipher Pharma Enters into Licensing Agreement with Aclaris Therapeutics 25
Vixen Pharma Enters into Licensing Agreement with Columbia University 26
Aclaris Therapeutics International Enters into Licensing Agreement with Rigel Pharma 27
Equity Offering 28
Aclaris Therapeutics Raises USD106.9 Million in Public Offering of Shares 28
Aclaris Therapeutics Raises USD86.3 Million in Public Offering of Shares 30
Aclaris Therapeutics Raises USD20 Million in Public Offering of Shares 32
Aclaris Therapeutics Raises USD104.7 Million in Public Offering of Shares 33
Aclaris Therapeutics Raises USD20 Million in Private Placement of Shares 35
Aclaris Therapeutics Raises USD63.3 Million in IPO 36
Acquisition 38
Aclaris Therapeutics Acquires Confluence Life Sciences 38
Aclaris Therapeutics to Acquire Vixen Pharma 39
Aclaris Therapeutics Inc – Key Competitors 40
Aclaris Therapeutics Inc – Key Employees 41
Aclaris Therapeutics Inc – Locations And Subsidiaries 42
Head Office 42
Other Locations & Subsidiaries 42
Recent Developments 43
Financial Announcements 43
Aug 03, 2018: Aclaris Therapeutics reports second quarter 2018 financial results and provides update on clinical and commercial developments 43
May 08, 2018: Aclaris Therapeutics Reports First Quarter 2018 Financial Results and Provides Update on Clinical and Commercial Developments 46
Mar 12, 2018: Aclaris Therapeutics Announces Fourth Quarter and Full Year 2017 Financial Results 49
Nov 07, 2017: Aclaris Therapeutics Reports Third Quarter 2017 Financial Results 53
Aug 08, 2017: Aclaris Therapeutics Reports Second Quarter 2017 Financial Results 57
May 09, 2017: Aclaris Therapeutics Reports First Quarter 2017 Financial Results 59
Mar 15, 2017: Aclaris Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update 61
Corporate Communications 63
Jun 15, 2018: Aclaris Therapeutics Appoints Dr. David Gordon As Chief Medical Officer 63
Apr 24, 2018: Aclaris Therapeutics Announces Names Bryan Reasons As Director And Chairman Of Audit Committee 64
Aug 09, 2017: Aclaris Announces Appointment of Andrew Schiff to Board of Directors 65
Jan 26, 2017: Aclaris Therapeutics Announces Appointment of Andrew Powell to Board of Directors 66
Product News 67
05/15/2018: Aclaris Therapeutics to Support Symposium on JAK Inhibitors at the International Investigative Dermatology 2018 Meeting 67
04/24/2017: Aclaris Therapeutics Hosts Symposium on JAK Inhibitors at the 76th Annual Society for Investigative Dermatology Meeting 68
Product Approvals 69
Aug 02, 2017: Aclaris Therapeutics Submits Investigational New Drug Application for ATI-50002 to Treat Alopecia Areata 69
Clinical Trials 70
Dec 19, 2017: Aclaris Therapeutics Initiates a Pilot Clinical Trial to Study ATI-50002 Topical in Patients with Vitiligo 70
May 05, 2017: Aclaris Therapeutics Completes Phase 1 Clinical Trial of ATI-50001 for the Treatment of Alopecia Universalis and Alopecia Totalis 71
Appendix 72
Methodology 72
About GlobalData 72
Contact Us 72
Disclaimer 72

List of Tables
Aclaris Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Aclaris Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Aclaris Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Aclaris Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Aclaris Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Aclaris Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10
Aclaris Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Aclaris Therapeutics to Acquire Worldwide Rights of RHOFADE from Allergan Sales 13
Confluence Life Sciences Raises USD4.8 Million in Financing 14
Aclaris Therapeutics Raises USD40 Million in Series C Financing 15
Confluence Life Sciences Raises USD2.4 Million in Post Seed Financing Round 17
Aclaris Therapeutics Raises USD21 Million in Series B Venture Financing 18
Confluence Life Sciences Raises Funds Through Venture Financing 19
Confluence Life Sciences Secures USD0.5 Million in Series A Funding Round 20
Aclaris Therapeutics Raises US$21 Million In Series A Financing 21
Confluence Life Sciences Raises US$4 Million In Series A Financing 23
Aclaris Therapeutics Enters Into Licensing Agreement with JAKPharm and Key Organics 24
Cipher Pharma Enters into Licensing Agreement with Aclaris Therapeutics 25
Vixen Pharma Enters into Licensing Agreement with Columbia University 26
Aclaris Therapeutics International Enters into Licensing Agreement with Rigel Pharma 27
Aclaris Therapeutics Raises USD106.9 Million in Public Offering of Shares 28
Aclaris Therapeutics Raises USD86.3 Million in Public Offering of Shares 30
Aclaris Therapeutics Raises USD20 Million in Public Offering of Shares 32
Aclaris Therapeutics Raises USD104.7 Million in Public Offering of Shares 33
Aclaris Therapeutics Raises USD20 Million in Private Placement of Shares 35
Aclaris Therapeutics Raises USD63.3 Million in IPO 36
Aclaris Therapeutics Acquires Confluence Life Sciences 38
Aclaris Therapeutics to Acquire Vixen Pharma 39
Aclaris Therapeutics Inc, Key Competitors 40
Aclaris Therapeutics Inc, Key Employees 41
Aclaris Therapeutics Inc, Subsidiaries 42

List of Figures
Aclaris Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Aclaris Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Aclaris Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Aclaris Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Aclaris Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Aclaris Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Aclaris Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Aclaris Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Aclaris Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Aclaris Therapeutics Inc (ACRS):製薬・医療:M&Aディール及び事業提携情報(Aclaris Therapeutics Inc (ACRS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆